Krish Patel, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    AstraZeneca
    Topic:
    CLL/Lymphoma
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Abbvie
    Topic:
    CLL/Lymphoma
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BeiGene
    Topic:
    CLL/Lymphoma
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    CLL/Lymphoma/Cell Therapy
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Caribou
    Topic:
    Cell Therapy
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Epizyme
    Topic:
    Lymphoma
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
    Relationship end date:
    12/31/2022
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Fate Therapeutics
    Topic:
    Cell Therapy
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Genentech
    Topic:
    CLL/Lymphoma
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Kite
    Topic:
    Cell Therapy
    Date added:
    02/09/2023
    Date updated:
    03/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen/Pharmacyclics
    Topic:
    CLL/Lymphoma
    Date added:
    02/09/2023
    Date updated:
    03/21/2024

Pages

Return to 2024 Summit on Hematological Cancers